Specialized Center Of Research In Osteoporosis View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

1987-2004

FUNDING AMOUNT

2923083 USD

ABSTRACT

Osteoporosis is recognized has a major public health problem in the USA today, with the likelihood of increased societal impact as "baby boomers" age. Therapeutic options are currently limited to "anti-resorptive" therapies which reduce bone turnover. Therapeutic options are currently limited to "anti-resorptive" therapies which reduce bone turnover, stabilize bone mass and reduce but not eliminate fracture risk, in part because many treated individuals are left with a bone mass that remains less than optimal. Thus, there is a clear need for agents that stimulate new bone formation. Our Specialized Center of Research has assembled a panoply of basic and clinical scientists to focus on this issue. Over the past 9 years we have investigated interactions of parathyroid hormone and sex steroids in the development and treatment of osteoporosis. Our cohesive and integrated approach has generated a significant base of knowledge, culminating in the demonstration that PTH (superimposed on standard HRT) not only increases bone mass but may also reduce vertebral fracture risk. In our current application, in four inter-related and integrated projects, we will examine aspects of PTH action at both basic and clinical levels. In Project 1 we will use novel techniques to isolate functional human osteoclasts and transgenic murine models to examine the mechanisms underlying osteoclast differentiation and death. In Project 2 the ovariectomized rat model will be used to evaluate morphological, biochemical, and mechanical responses to PTH, comparing a model of primary hyperparathyroidism (continuous PTH infusion) with intermittent PTH administration, in both estrogen replete and depleted states. The next project uses the paradigm of endogenous primary hyperparathyroidism in post-menopausal women to characterize the effects of chronically increased PTH, and its reduction (after parathyroidectomy) on skeletal homeostasis. The last project focusses on the mechanism underlying the initial period of new bone formation that occurs in the early months of PTH therapy, as well as the effects of withdrawal of treatment. Each of these projects relies heavily on the support of "Core" units,: Administration/Statistics; Biochemistry; Histomorphometry; and Bone Mass Measurement, with integration of all Projects and Cores with regard to protocols, investigators and data interpretation. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=6534410

Related SciGraph Publications

  • 2004-12. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)] in OSTEOPOROSIS INTERNATIONAL
  • 2002-05. The Impact of Bone Turnover and Bone-Active Agents on Bone Quality: Focus on the Hip in OSTEOPOROSIS INTERNATIONAL
  • 2002-04. The Anabolic Effects of Parathyroid Hormone in OSTEOPOROSIS INTERNATIONAL
  • 2002. Human Cathepsins W and F form A New Subgroup of Cathepsins that is Evolutionary Separated from the Cathepsin B- and L-Like Cysteine Proteases in CELLULAR PEPTIDASES IN IMMUNE FUNCTIONS AND DISEASES 2
  • 2000-11. Clinical Spectrum of Primary Hyperparathyroidism in REVIEWS IN ENDOCRINE AND METABOLIC DISORDERS
  • 1998-08. Comparative Assessment of Bone Mineral Measurements Using Dual X-ray Absorptiometry and Peripheral Quantitative Computed Tomography in OSTEOPOROSIS INTERNATIONAL
  • 1998-06. Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence in CALCIFIED TISSUE INTERNATIONAL
  • 1997-08. Reduced Bone Mass and Fat-Free Mass in Women with Multiple Sclerosis: Effects of Ambulatory Status and Glucocorticoid Use in CALCIFIED TISSUE INTERNATIONAL
  • 1996-08. Effect of diacylglycerols on osteoclastic bone resorption in CALCIFIED TISSUE INTERNATIONAL
  • 1996-04. Bone density change and biochemical indices of skeletal turnover in CALCIFIED TISSUE INTERNATIONAL
  • 1995-07. Lack of significant effect of carboxyl-terminal parathyroid hormone-related peptide fragments on isolated rat and chick osteoclasts in CALCIFIED TISSUE INTERNATIONAL
  • 1993-03. Relationships between bone structure in the iliac crest and bone structure and strength in the lumbar spine in OSTEOPOROSIS INTERNATIONAL
  • 1992-11. Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry in CALCIFIED TISSUE INTERNATIONAL
  • 1992-03. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1–34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia in CALCIFIED TISSUE INTERNATIONAL
  • 1991-07. Effects of cyclosporine a on chick osteoclastsIn vitro in CALCIFIED TISSUE INTERNATIONAL
  • 1991-01. Radiographic absorptiometry: A simple method for determination of bone mass in OSTEOPOROSIS INTERNATIONAL
  • 1990-10. Estrogens, bone loss and preservation in OSTEOPOROSIS INTERNATIONAL
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "2923083"
        }, 
        "description": "Osteoporosis is recognized has a major public health problem in the USA today, with the likelihood of increased societal impact as \"baby boomers\" age. Therapeutic options are currently limited to \"anti-resorptive\" therapies which reduce bone turnover. Therapeutic options are currently limited to \"anti-resorptive\" therapies which reduce bone turnover, stabilize bone mass and reduce but not eliminate fracture risk, in part because many treated individuals are left with a bone mass that remains less than optimal. Thus, there is a clear need for agents that stimulate new bone formation. Our Specialized Center of Research has assembled a panoply of basic and clinical scientists to focus on this issue. Over the past 9 years we have investigated interactions of parathyroid hormone and sex steroids in the development and treatment of osteoporosis. Our cohesive and integrated approach has generated a significant base of knowledge, culminating in the demonstration that PTH (superimposed on standard HRT) not only increases bone mass but may also reduce vertebral fracture risk. In our current application, in four inter-related and integrated projects, we will examine aspects of PTH action at both basic and clinical levels. In Project 1 we will use novel techniques to isolate functional human osteoclasts and transgenic murine models to examine the mechanisms underlying osteoclast differentiation and death. In Project 2 the ovariectomized rat model will be used to evaluate morphological, biochemical, and mechanical responses to PTH, comparing a model of primary hyperparathyroidism (continuous PTH infusion) with intermittent PTH administration, in both estrogen replete and depleted states. The next project uses the paradigm of endogenous primary hyperparathyroidism in post-menopausal women to characterize the effects of chronically increased PTH, and its reduction (after parathyroidectomy) on skeletal homeostasis. The last project focusses on the mechanism underlying the initial period of new bone formation that occurs in the early months of PTH therapy, as well as the effects of withdrawal of treatment. Each of these projects relies heavily on the support of \"Core\" units,: Administration/Statistics; Biochemistry; Histomorphometry; and Bone Mass Measurement, with integration of all Projects and Cores with regard to protocols, investigators and data interpretation.", 
        "endDate": "2004-08-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.420086.8", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2440076", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2440076"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "P50AR039191"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "major public health problem", 
          "continuous PTH infusion", 
          "parathyroidectomy", 
          "agents", 
          "treatment", 
          "units", 
          "research", 
          "last project focusses", 
          "primary hyperparathyroidism", 
          "endogenous primary hyperparathyroidism", 
          "development", 
          "knowledge", 
          "baby boomers", 
          "bone mass measurements", 
          "PTH", 
          "vertebral fracture risk", 
          "core", 
          "Projects", 
          "mechanical response", 
          "clear need", 
          "fracture risk", 
          "estrogen", 
          "parathyroid hormone", 
          "PTH action", 
          "clinical scientists", 
          "reduction", 
          "current applications", 
          "data interpretation", 
          "integration", 
          "demonstration", 
          "sex steroids", 
          "inter", 
          "support", 
          "years", 
          "depleted state", 
          "bone mass", 
          "Statistics", 
          "Cores", 
          "standard HRT", 
          "next project", 
          "new bone formation", 
          "clinical level", 
          "early months", 
          "skeletal homeostasis", 
          "panoply", 
          "USA Today", 
          "individuals", 
          "integrated approach", 
          "likelihood", 
          "novel technique", 
          "Project 1", 
          "RESEARCH IN OSTEOPOROSIS", 
          "mechanism", 
          "issues", 
          "death", 
          "transgenic murine model", 
          "part", 
          "specialized centers", 
          "therapy", 
          "post-menopausal women", 
          "Project 2", 
          "effect", 
          "administration", 
          "osteoclast differentiation", 
          "functional human osteoclasts", 
          "histomorphometry", 
          "bone turnover", 
          "protocol", 
          "initial period", 
          "paradigm", 
          "withdrawal", 
          "osteoporosis", 
          "project", 
          "therapeutic options", 
          "biochemistry", 
          "model", 
          "age", 
          "ovariectomized rat model", 
          "PTH therapy", 
          "societal impact", 
          "significant base", 
          "investigators", 
          "intermittent PTH administration", 
          "aspects", 
          "regard", 
          "interaction"
        ], 
        "name": "SPECIALIZED CENTER OF RESEARCH IN OSTEOPOROSIS", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.413989.e", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.413989.e", 
              "name": "HELEN HAYES HOSPITAL", 
              "type": "Organization"
            }, 
            "familyName": "LINDSAY", 
            "givenName": "ROBERT", 
            "id": "sg:person.01230350641.01", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.01230350641.01", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2440076"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_4.xml.gz", 
        "startDate": "1987-09-30T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=6534410"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2440076'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2440076'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2440076'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2440076'


     

    This table displays all metadata directly associated to this object as RDF triples.

    130 TRIPLES      19 PREDICATES      108 URIs      100 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2440076 schema:about anzsrc-for:2211
    2 schema:amount N0713cb0601b74c0e82c408f95a2fc8fd
    3 schema:description Osteoporosis is recognized has a major public health problem in the USA today, with the likelihood of increased societal impact as "baby boomers" age. Therapeutic options are currently limited to "anti-resorptive" therapies which reduce bone turnover. Therapeutic options are currently limited to "anti-resorptive" therapies which reduce bone turnover, stabilize bone mass and reduce but not eliminate fracture risk, in part because many treated individuals are left with a bone mass that remains less than optimal. Thus, there is a clear need for agents that stimulate new bone formation. Our Specialized Center of Research has assembled a panoply of basic and clinical scientists to focus on this issue. Over the past 9 years we have investigated interactions of parathyroid hormone and sex steroids in the development and treatment of osteoporosis. Our cohesive and integrated approach has generated a significant base of knowledge, culminating in the demonstration that PTH (superimposed on standard HRT) not only increases bone mass but may also reduce vertebral fracture risk. In our current application, in four inter-related and integrated projects, we will examine aspects of PTH action at both basic and clinical levels. In Project 1 we will use novel techniques to isolate functional human osteoclasts and transgenic murine models to examine the mechanisms underlying osteoclast differentiation and death. In Project 2 the ovariectomized rat model will be used to evaluate morphological, biochemical, and mechanical responses to PTH, comparing a model of primary hyperparathyroidism (continuous PTH infusion) with intermittent PTH administration, in both estrogen replete and depleted states. The next project uses the paradigm of endogenous primary hyperparathyroidism in post-menopausal women to characterize the effects of chronically increased PTH, and its reduction (after parathyroidectomy) on skeletal homeostasis. The last project focusses on the mechanism underlying the initial period of new bone formation that occurs in the early months of PTH therapy, as well as the effects of withdrawal of treatment. Each of these projects relies heavily on the support of "Core" units,: Administration/Statistics; Biochemistry; Histomorphometry; and Bone Mass Measurement, with integration of all Projects and Cores with regard to protocols, investigators and data interpretation.
    4 schema:endDate 2004-08-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.420086.8
    6 schema:identifier N2a752e9b51234f1ca04c9a62016c88f9
    7 Ne033be1db5b6446992a63dadfcb3aea6
    8 schema:inLanguage en
    9 schema:keywords Cores
    10 PTH
    11 PTH action
    12 PTH therapy
    13 Project 1
    14 Project 2
    15 Projects
    16 RESEARCH IN OSTEOPOROSIS
    17 Statistics
    18 USA Today
    19 administration
    20 age
    21 agents
    22 aspects
    23 baby boomers
    24 biochemistry
    25 bone mass
    26 bone mass measurements
    27 bone turnover
    28 clear need
    29 clinical level
    30 clinical scientists
    31 continuous PTH infusion
    32 core
    33 current applications
    34 data interpretation
    35 death
    36 demonstration
    37 depleted state
    38 development
    39 early months
    40 effect
    41 endogenous primary hyperparathyroidism
    42 estrogen
    43 fracture risk
    44 functional human osteoclasts
    45 histomorphometry
    46 individuals
    47 initial period
    48 integrated approach
    49 integration
    50 inter
    51 interaction
    52 intermittent PTH administration
    53 investigators
    54 issues
    55 knowledge
    56 last project focusses
    57 likelihood
    58 major public health problem
    59 mechanical response
    60 mechanism
    61 model
    62 new bone formation
    63 next project
    64 novel technique
    65 osteoclast differentiation
    66 osteoporosis
    67 ovariectomized rat model
    68 panoply
    69 paradigm
    70 parathyroid hormone
    71 parathyroidectomy
    72 part
    73 post-menopausal women
    74 primary hyperparathyroidism
    75 project
    76 protocol
    77 reduction
    78 regard
    79 research
    80 sex steroids
    81 significant base
    82 skeletal homeostasis
    83 societal impact
    84 specialized centers
    85 standard HRT
    86 support
    87 therapeutic options
    88 therapy
    89 transgenic murine model
    90 treatment
    91 units
    92 vertebral fracture risk
    93 withdrawal
    94 years
    95 schema:name SPECIALIZED CENTER OF RESEARCH IN OSTEOPOROSIS
    96 schema:recipient Nba47d62595f54cc58624519d23fb114d
    97 sg:person.01230350641.01
    98 https://www.grid.ac/institutes/grid.413989.e
    99 schema:sameAs https://app.dimensions.ai/details/grant/grant.2440076
    100 schema:sdDatePublished 2019-03-07T12:11
    101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    102 schema:sdPublisher N5af1d3e731c041c0bf93a797ba678b01
    103 schema:startDate 1987-09-30T00:00:00Z
    104 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=6534410
    105 sgo:license sg:explorer/license/
    106 sgo:sdDataset grants
    107 rdf:type schema:MonetaryGrant
    108 N0713cb0601b74c0e82c408f95a2fc8fd schema:currency USD
    109 schema:value 2923083
    110 rdf:type schema:MonetaryAmount
    111 N2a752e9b51234f1ca04c9a62016c88f9 schema:name nih_id
    112 schema:value P50AR039191
    113 rdf:type schema:PropertyValue
    114 N5af1d3e731c041c0bf93a797ba678b01 schema:name Springer Nature - SN SciGraph project
    115 rdf:type schema:Organization
    116 Nba47d62595f54cc58624519d23fb114d schema:member sg:person.01230350641.01
    117 schema:roleName PI
    118 rdf:type schema:Role
    119 Ne033be1db5b6446992a63dadfcb3aea6 schema:name dimensions_id
    120 schema:value 2440076
    121 rdf:type schema:PropertyValue
    122 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    123 rdf:type schema:DefinedTerm
    124 sg:person.01230350641.01 schema:affiliation https://www.grid.ac/institutes/grid.413989.e
    125 schema:familyName LINDSAY
    126 schema:givenName ROBERT
    127 rdf:type schema:Person
    128 https://www.grid.ac/institutes/grid.413989.e schema:name HELEN HAYES HOSPITAL
    129 rdf:type schema:Organization
    130 https://www.grid.ac/institutes/grid.420086.8 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...